Literature DB >> 14603260

PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression.

Maria-Cristina Seminario1, Patricia Precht, Robert P Wersto, Myriam Gorospe, Ronald L Wange.   

Abstract

The balance of activities between the proto-oncogene phosphoinositide 3-kinase (PI3K) and the tumour suppressor gene PTEN has been shown to affect cellular growth and proliferation, as well as tumorigenesis. Previously, PTEN expression in the PTEN-null Jurkat T cell leukaemia line was shown to cause reduced proliferation without cell cycle arrest. Here, we further these investigations by determining the basis for this phenomenon. By BrdU pulse-chase and cell cycle arrest and release assays, we find that PTEN expression reduced proliferation by slowing progression through all phases of the cell cycle. This was associated with reduced levels of cyclins A, B1 and B2, cdk4, and cdc25A and increased p27KIP1 expression. Apoptosis played no role in the antiproliferative effect of PTEN, since only marginal increases in the rate of apoptosis were detected upon PTEN expression, and inhibitors of effector caspases did not restore proliferative capacity. Active Akt blocked the antiproliferative effects of PTEN, indicating that PTEN mediates its effects through conventional PI3K-linked signalling pathways. Similar results were obtained from a different PTEN-null leukaemia T cell line, CEM. Together, these results show that PTEN expression in leukaemic T cells leads to reduced proliferation via an apoptosis-independent mechanism involving slower passage through the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14603260     DOI: 10.1038/sj.onc.1206872

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Inhibition of mast cell degranulation by a chimeric toxin containing a novel phosphatidylinositol-3,4,5-triphosphate phosphatase.

Authors:  Bruce J Shenker; Kathleen Boesze-Battaglia; Ali Zekavat; Lisa Walker; Dave Besack; Hydar Ali
Journal:  Mol Immunol       Date:  2010-09-21       Impact factor: 4.407

2.  Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN.

Authors:  Ping Gao; Ronald L Wange; Ning Zhang; Joost J Oppenheim; O M Zack Howard
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  Lymphoid susceptibility to the Aggregatibacter actinomycetemcomitans cytolethal distending toxin is dependent upon baseline levels of the signaling lipid, phosphatidylinositol-3,4,5-triphosphate.

Authors:  B J Shenker; L P Walker; A Zekavat; K Boesze-Battaglia
Journal:  Mol Oral Microbiol       Date:  2015-09-24       Impact factor: 3.563

4.  PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.

Authors:  Patrick T Walsh; Jodi L Buckler; Jidong Zhang; Andrew E Gelman; Nicole M Dalton; Devon K Taylor; Steven J Bensinger; Wayne W Hancock; Laurence A Turka
Journal:  J Clin Invest       Date:  2006-08-17       Impact factor: 14.808

5.  A novel mode of action for a microbial-derived immunotoxin: the cytolethal distending toxin subunit B exhibits phosphatidylinositol 3,4,5-triphosphate phosphatase activity.

Authors:  Bruce J Shenker; Mensur Dlakic; Lisa P Walker; Dave Besack; Eileen Jaffe; Ed LaBelle; Kathleen Boesze-Battaglia
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

6.  Growth suppression of human lung cancer cells and implanted tumors by adenovirus-mediated transfer of the PTEN gene.

Authors:  Zhixiong Chen; Jiong Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

7.  Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells.

Authors:  Young-Rae Lee; Hong-Nu Yu; Eun-Mi Noh; Jong-Suk Kim; Eun-Kyung Song; Myung-Kwan Han; Byeong-Soo Kim; Sung-Ho Lee; Jinny Park
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

8.  Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.

Authors:  Federica Falà; William L Blalock; Pier Luigi Tazzari; Alessandra Cappellini; Francesca Chiarini; Giovanni Martinelli; Agostino Tafuri; James A McCubrey; Lucio Cocco; Alberto M Martelli
Journal:  Mol Pharmacol       Date:  2008-06-24       Impact factor: 4.436

Review 9.  PIP3 pathway in regulatory T cells and autoimmunity.

Authors:  Masaki Kashiwada; Ping Lu; Paul B Rothman
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.

Authors:  Nichola Cruickshanks; Yong Tang; Laurence Booth; Hossein Hamed; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2012-09-18       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.